Aktie A14XCV ZYNERBA PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Zynerba Pharmaceuticals, Inc.

Aktien

A14XCV

US98986X1090

ZYNE

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE - Zynerba
Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index
Harmony Biosciences Holdings Completes Acquisition of Zynerba Pharmaceuticals
Zynerba Pharmaceuticals : Acquisition/Asset Disposal - Form 8-K
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
Fragile X Syndrome Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
Harmony Biosciences Holdings, Inc. completed the acquisition of Zynerba Pharmaceuticals, Inc..
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions - Zynerba
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares before 5:00 PM New York City Time, on Tuesday October 10, 2023
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 - Zynerba
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index
Harmony Biosciences Says its Xylophone Acquisition Unit Extends Tender Offer for Zynerba Pharmaceuticals to Oct. 10
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
Shareholder Alert: Ademi LLP investigates whether Zynerba Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Harmony
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A14XCV Aktie
  4. Nachrichten Zynerba Pharmaceuticals, Inc.
  5. Andere Sprachen